Article Versions Notes

Nyffenegger N, Flace A, Doucerain C, Dürrenberger F, Manolova V. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia. International Journal of Molecular Sciences. 2021; 22(2):873. https://doi.org/10.3390/ijms22020873

Nyffenegger, Naja, Anna Flace, Cédric Doucerain, Franz Dürrenberger, and Vania Manolova. 2021. "The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia" International Journal of Molecular Sciences 22, no. 2: 873. https://doi.org/10.3390/ijms22020873

Nyffenegger, N., Flace, A., Doucerain, C., Dürrenberger, F., & Manolova, V. (2021). The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia. International Journal of Molecular Sciences, 22(2), 873. https://doi.org/10.3390/ijms22020873